LAKE FOREST, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ: AKRX) today announced the commercial launch of Akten™ Gel 3.5%, a topical ocular anesthetic ophthalmic drug product. Akten™ represents the first FDA approved drug product indicated for use as an ocular anesthetic in four decades. Akten™ is the only approved ocular gel formulation that also contains the highest concentration of lidocaine. Akten™ has several unique features: it is preservative free, non toxic to the cornea, does not sting due to its physiological pH and can be stored at room temperature. Akten™ can be used as a local anesthetic indicated for ocular surface anesthesia during ophthalmologic procedures. Examples of these procedures include cataract/glaucoma surgery, intravitreal injections for retinal disorders, retina surgery, and miscellaneous ocular procedures both in hospital/clinics and office based practices.
